294 related articles for article (PubMed ID: 17425689)
1. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis.
Kobayashi S; Kishimoto T; Kamata S; Otsuka M; Miyazaki M; Ishikura H
Cancer Sci; 2007 May; 98(5):726-33. PubMed ID: 17425689
[TBL] [Abstract][Full Text] [Related]
2. Lipopolysaccharide increases the release of VEGF-C that enhances cell motility and promotes lymphangiogenesis and lymphatic metastasis through the TLR4- NF-κB/JNK pathways in colorectal cancer.
Zhu G; Huang Q; Huang Y; Zheng W; Hua J; Yang S; Zhuang J; Wang J; Ye J
Oncotarget; 2016 Nov; 7(45):73711-73724. PubMed ID: 27713159
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.
Huber S; Bruns CJ; Schmid G; Hermann PC; Conrad C; Niess H; Huss R; Graeb C; Jauch KW; Heeschen C; Guba M
Kidney Int; 2007 Apr; 71(8):771-7. PubMed ID: 17299523
[TBL] [Abstract][Full Text] [Related]
4. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
[TBL] [Abstract][Full Text] [Related]
5. Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway.
Huang B; Lu Y; Gui M; Guan J; Lin M; Zhao J; Mao Q; Lin J
Biomed Pharmacother; 2021 May; 137():111331. PubMed ID: 33578235
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C.
Liu H; Yang Y; Xiao J; Lv Y; Liu Y; Yang H; Zhao L
Anat Rec (Hoboken); 2009 Oct; 292(10):1577-83. PubMed ID: 19685508
[TBL] [Abstract][Full Text] [Related]
7. KAI1 inhibits lymphangiogenesis and lymphatic metastasis of pancreatic cancer in vivo.
Liu X; Guo XZ; Li HY; Chen J; Ren LN; Wu CY
Hepatobiliary Pancreat Dis Int; 2014 Feb; 13(1):87-92. PubMed ID: 24463085
[TBL] [Abstract][Full Text] [Related]
8. Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models.
Ekshyyan O; Moore-Medlin TN; Raley MC; Sonavane K; Rong X; Brodt MA; Abreo F; Alexander JS; Nathan CA
BMC Cancer; 2013 Jul; 13():320. PubMed ID: 23815869
[TBL] [Abstract][Full Text] [Related]
9. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
10. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
[TBL] [Abstract][Full Text] [Related]
11. Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C.
Wang J; Zhang B; Guo Y; Li G; Xie Q; Zhu B; Gao J; Chen Z
Pharmacology; 2008; 82(2):148-55. PubMed ID: 18667841
[TBL] [Abstract][Full Text] [Related]
12. Effects of 6,8-Diprenylgenistein on VEGF-A-Induced Lymphangiogenesis and Lymph Node Metastasis in an Oral Cancer Sentinel Lymph Node Animal Model.
Bae MG; Hwang-Bo J; Lee DY; Lee YH; Chung IS
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466636
[TBL] [Abstract][Full Text] [Related]
13. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.
Matsui J; Funahashi Y; Uenaka T; Watanabe T; Tsuruoka A; Asada M
Clin Cancer Res; 2008 Sep; 14(17):5459-65. PubMed ID: 18765537
[TBL] [Abstract][Full Text] [Related]
14. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer.
Kong Y; Li Y; Luo Y; Zhu J; Zheng H; Gao B; Guo X; Li Z; Chen R; Chen C
Mol Cancer; 2020 May; 19(1):82. PubMed ID: 32366257
[TBL] [Abstract][Full Text] [Related]
15. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
Bhola P; Banerjee S; Mukherjee J; Balasubramanium A; Arun V; Karim Z; Burrell K; Croul S; Gutmann DH; Guha A
Int J Cancer; 2010 Jan; 126(2):563-71. PubMed ID: 19634141
[TBL] [Abstract][Full Text] [Related]
16. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
Von Marschall Z; Scholz A; Stacker SA; Achen MG; Jackson DG; Alves F; Schirner M; Haberey M; Thierauch KH; Wiedenmann B; Rosewicz S
Int J Oncol; 2005 Sep; 27(3):669-79. PubMed ID: 16077915
[TBL] [Abstract][Full Text] [Related]
18. WISP-1 promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-300 in human oral squamous cell carcinoma cells.
Lin CC; Chen PC; Lein MY; Tsao CW; Huang CC; Wang SW; Tang CH; Tung KC
Oncotarget; 2016 Mar; 7(9):9993-10005. PubMed ID: 26824419
[TBL] [Abstract][Full Text] [Related]
19. VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway.
Villaume K; Blanc M; Gouysse G; Walter T; Couderc C; Nejjari M; Vercherat C; Cordier-Bussat M; Roche C; Scoazec JY
Neuroendocrinology; 2010; 91(3):268-78. PubMed ID: 20389030
[TBL] [Abstract][Full Text] [Related]
20. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
Yang H; Kim C; Kim MJ; Schwendener RA; Alitalo K; Heston W; Kim I; Kim WJ; Koh GY
Mol Cancer; 2011 Apr; 10():36. PubMed ID: 21481239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
